 |
|
|
| |
REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR: DATA FROM THE GERMAN HEPATITIS C-REGISTRY
|
| |
| |
Reported by Jules Levin
EASL 2019 April 10-14 Vienna
Markus Cornberg1, Albrecht Stoehr2, Uwe Naumann3, Hartwig Klinker4, Thomas Lutz5, Willibold Schiffelholz6, NazifaQurishi7, Andreas Pangerl8,Kristina Lohmann8, Bettina Koenig8, Karl-Georg Simon9
1MedizinischeHochschule Hannover, KlinikfürGastroenterologie, Hepatologieund Endokrinologie, Hannover, Germany; 2. IFIStudienund ProjekteGmbH, Hamburg, Germany; 3. UBN-Praxis, Berlin, Germany; 4. University Hospital Würzburg, Würzburg, Germany; 5. Infektiologikum, Frankfurt, Germany; 6. GastroenterologischeSchwerpunktpraxis, Augsburg, Germany; 7. GemeinschaftspraxisGotenring, Cologne, Germany; 8. AbbVie Inc., North Chicago, Illinois, USA; 9. MVZDresEisenbach/Simon/ Schwarz/GbR, Leverkusen, Germany
|
| |
|
|
|
|
|
